Skip to main content

Advertisement

SpringerLink
Log in

Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions

  • Educational Series/Yellow Series
  • Advances in Clinical Management and Therapy of Cancer
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Lung cancer is the most frequent cause of cancer death worldwide and its global incidence has been steadily increasing during recent decades. A third of patients with newly diagnosed non-small-cell lung cancer (NSCLC) present with locally advanced disease. There is not a single widely accepted standard of care for these patients because of the wide spectrum of presentation of the disease. Although feasible and safe in experienced hands, evidence that surgical resection after induction treatment improves overall survival (OS) is lacking. For resectable or potentially resectable stage III, the findings of two phase III trials suggest that surgical resection should not be considered a standard of care but rather reserved for selected patients after critical multidisciplinary assessment, in whom surgery improves survival after downstaging if pneumonectomy can be avoided or in some T4N0-1 resectable tumours. For unresectable stage III NSCLC the standard of care is a combination of chemotherapy and radiotherapy. In those patients with good performance status and minimal weight loss, the concurrent approach has resulted in a statistically significant improvement in OS rates compared with a sequential approach in randomised clinical trials, although several questions remain unresolved.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Bray F, Ferlay J et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  2. Roth JA, Fossella F, Komaki R et al (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:673–680

    Article  PubMed  CAS  Google Scholar 

  3. Rosell R, Gomez-Codina J, Camps C et al (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153–158

    Article  PubMed  CAS  Google Scholar 

  4. Albain KS, Rusch VW, Crowley JJ et al (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880–1892

    PubMed  CAS  Google Scholar 

  5. Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374:379–386

    Article  PubMed  CAS  Google Scholar 

  6. Van Meerbeeck JP, Kramer GW, van Schil PE et al (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99:442–450

    Article  PubMed  Google Scholar 

  7. Higgins K, Chino JP, Marks LB et al (2009) Preoperative chemotherapy versus preoperative chamoradiotherapy for stage III (N2) non-small cell lung cancer. Int J Radiat Oncol Biol Phys 75:1462–1467

    Article  PubMed  CAS  Google Scholar 

  8. Thomas M, Rübe C, Hoffknecht P et al (2008) Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomized trial in stage III non-small cell lung cancer. Lancet Oncol 9:607–608

    Article  Google Scholar 

  9. De Cabanyes Candela S, Detterbeck FC (2010) A systematic review of restaging after induction therapy for stage IIIA lung cancer: prediction of pathologic stage. J Thorac Oncol 5:389–398

    Article  PubMed  Google Scholar 

  10. National Comprehensive Cancer Network (2011) NCCN Guidelines Version 3. National Comprehensive Cancer Network

  11. Sonett JR, Suntharalingam M, Edelman MJ et al (2004) Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small cell lung cancer. Ann Thorac Surg 78:1200–1205

    Article  PubMed  Google Scholar 

  12. Bauman JE, Mulligan MS, Martins RG et al (2008) Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg 86:1632–1639

    Article  PubMed  Google Scholar 

  13. Hürtgen M, Friedel G, Toomes H et al (2002) Radical video-assisted mediastinoscopic lymphadenectomy (VAMLA): technique and first results. Eur J Cardiothorac Surg 21:348–351

    Article  PubMed  Google Scholar 

  14. Kuzdzal J, Zielinski M, Papla B et al (2005) Transcervical extended mediastinal lymphadenectomy: the new operative technique and early results in lung cancer staging. Eur J Cardiothorac Surg 27:384–390

    Article  PubMed  Google Scholar 

  15. Asamura H, Suzuki K, Kondo H et al (2000) Where is the boundary between N1 and N2 stations in lung cancer? Ann Thorac Surg 70:1839–1846

    Article  PubMed  CAS  Google Scholar 

  16. Rusch VW, Crowley J, Giroux DJ et al (2007) International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating; Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2:603–612

    Article  PubMed  Google Scholar 

  17. Stefani A, Alifano M, Bobbio A et al (2010) Which patients should be operated on after induction che?motherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients. J Thorac Cardiovasc Surg 140:356–363

    Article  PubMed  Google Scholar 

  18. Albain K, Rusch V, Crowley J et al (1999) Longterm survival after concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer: 6-year outcomes from Southwest Oncology Group Study 8805. Proc Am Soc Clin Oncol 18:467a (abstr)

    Google Scholar 

  19. Yang HX, Hou X, Lin P et al (2009) Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer. Ann Thorac Surg 88:372–378

    Article  PubMed  Google Scholar 

  20. Wu L, Xu Z, Zhao X et al (2009) Surgical treatment of lung cancer invading the left atrium or base of the pulmonary vein. World J Surg 33:492–496

    Article  PubMed  Google Scholar 

  21. Garrido P, González-Larriba JL, Insa A et al (2007) Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 25:4736–4742

    Article  PubMed  Google Scholar 

  22. Bryant AS, Pereira SJ, Miller DL et al (2006) Satellite pulmonary nodule in the same lobe (T4N0) should not be staged as IIIB non-small cell lung cancer. Ann Thorac Surg 82:1808–1813; discussion 13–14

    Article  PubMed  Google Scholar 

  23. Dartevelle PG, Khalife J, Chapelier A et al (1988) Tracheal sleeve pneumonectomy for bronchogenic carcinoma: a report of 55 cases. Ann Thorac Surg 46:68–72

    Article  PubMed  CAS  Google Scholar 

  24. Mathisen DJ, Grillo HC (1991) Carinal resection for bronchogenic carcinoma. Thorac Cardiovasc Surg 102:16–22; discussion 22–23

    CAS  Google Scholar 

  25. Rice TW, Blackstone EH (2002) Radical resections for T4 lung cancer. Surg Clin North Am 82: 573–587

    Article  PubMed  Google Scholar 

  26. Martin-Ucar AE, Chaudhuri N, Edwards JG et al (2002) Can pneumonectomy of non-small cell lung cancer be avoided? An audit of parenchymal sparing lung surgery. Eur J Cardiothorac Surg 21: 601–605

    Article  PubMed  CAS  Google Scholar 

  27. Melloul E, Egger B, Krueger T et al (2008) Mortality, complications and loss of pulmonary function after pneumonectomy vs. sleeve lobectomy in patients younger and older than 70 years. Interact CardioVasc Thorac Surg 7:986–989

    Article  PubMed  Google Scholar 

  28. Ferguson MK, Lehman AG (2003) Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg 76:1782–1788

    Article  PubMed  Google Scholar 

  29. Ma Z, Dong A, Fan J et al (2007) Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis. Eur J Cardiothorac Surg 32:20–28

    Article  PubMed  CAS  Google Scholar 

  30. Allen AM, Mentzer SJ, Yeap BY et al (2008) Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 112:1106–1113

    Article  PubMed  Google Scholar 

  31. Thibout Y, Guibert B, Bossard N et al (2009) Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases. J Thorac Oncol 4:1496–1503

    Article  PubMed  Google Scholar 

  32. Weder W, Collaud S, Eberhardt WE et al (2010) Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III nonsmall-cell lung cancer. J Thorac Cardiovasc Surg 139:1424–1430

    Article  PubMed  Google Scholar 

  33. Petrella F, Radice D, Borri A et al (2011) The impact of preoperative body mass index on respiratory complications after pneumonectomy for non-small-cell lung cancer. Results from a series of 154 consecutive standard pneumonectomies. Eur J Cardiothorac Surg 39:738–744

    Article  PubMed  Google Scholar 

  34. D'Amato TA, Ashrafi AS, Schuchert MJ et al (2009) Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 88:1079–1085

    Article  PubMed  Google Scholar 

  35. Shapiro M, Swanson SJ, Wright CD et al (2010) Predictors of major morbidity and mortality after pneumonectomy utilizing the Society for Thoracic Surgeons General Thoracic Surgery Database. Ann Thorac Surg 90:927–934; discussion 934–935

    Article  PubMed  Google Scholar 

  36. Leo F, Scanagatta P, Vannucci F et al (2010) Impaired quality of life after pneumonectomy: who is at risk? J Thorac Cardiovasc Surg 139:49–52

    Article  PubMed  Google Scholar 

  37. Veen EJ, Janssen-Heijnen ML, Ritchie ED et al (2009) Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome. Interact Cardiovasc Thorac Surg 9:260–264

    Article  PubMed  Google Scholar 

  38. Dillman RO, Seagren SL, Propert KJ et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940–945

    Article  PubMed  CAS  Google Scholar 

  39. Sause W, Kolesar P, Taylor S IV et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364

    Article  PubMed  CAS  Google Scholar 

  40. Pritchard RS, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable non small cell lung cancer. A metaanalysis. Ann Intern Med 125:723–729

    CAS  Google Scholar 

  41. Rolland E, Le Chevalier T, Aupérin A et al (2007) Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): two meta-analyses using individual patient data (IPD) from randomised clinical trials (RCTs): A1-04. J Thorac Oncol 2: S309–S310

    Article  Google Scholar 

  42. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non small cell lung cancer. J Clin Oncol 17:2692–2699

    PubMed  CAS  Google Scholar 

  43. Curran W, Scott C, Langer C et al (2003) Longterm benefit is observed in a phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non small cell lung cancer: Radiation Therapy Oncology Group 9410. J Clin Oncol ASCO Annual Meeting Proceedings Part I, Vol 22; 621 (2499)

    Google Scholar 

  44. Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23: 5910–5917

    Article  PubMed  CAS  Google Scholar 

  45. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909

    Google Scholar 

  46. Auperin A, Le Pechoux C, Pignon JP et al; on behalf of the Meta-Analysis of Cisplatin/Carboplatin Based Concomitant Chemotherapy in Non-small cell Lung Cancer (MAC3-LC) Group (2006) Concomitant radiochemotherapy based on platin compounds in patients with locally advanced nonsmall cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 17:473–483

    Article  PubMed  CAS  Google Scholar 

  47. Auperin A, Le Pechoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-smallcell lung cancer. J Clin Oncol 28:2181–2190

    Article  PubMed  CAS  Google Scholar 

  48. Garrido P, Rosell R, Massutí B et al (2009) Predictors of long-term survival in lung cancer patients included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. Clin Lung Cancer 10:180–186

    Article  PubMed  CAS  Google Scholar 

  49. Albain KS, Crowley JJ, Turrisi AT III et al (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454–3460

    Article  PubMed  CAS  Google Scholar 

  50. Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004–2010

    Article  PubMed  CAS  Google Scholar 

  51. Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755–5760

    Article  PubMed  CAS  Google Scholar 

  52. Vokes EE, Herndon JE II, Crawford J et al (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20:4191–4198

    Article  PubMed  CAS  Google Scholar 

  53. Belani CP, Choy H, Bonomi P et al (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-smallcell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883–5891

    Article  PubMed  CAS  Google Scholar 

  54. Vokes EE, Herdon JE II, Kelly MJ et al (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698–1704

    Article  PubMed  CAS  Google Scholar 

  55. Kelly K, Chansky K, Gaspar LE et al (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-smallcell lung cancer: SWOG S0023. J Clin Oncol 26:2450–2456

    Article  PubMed  CAS  Google Scholar 

  56. Radiation Therapy Oncology Group. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel +/− cetuximab in patients with stage IIIA/IIIB non-small cell lung cancer. RTOG-0617, NCCTG-N0628, CALGB-30609. ClinicalTrials.gov Id NCT00533949

  57. Provencio M, Sánchez A, Garrido P et al (2010) New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 11:91–97

    Article  PubMed  CAS  Google Scholar 

  58. Perez CA, Stanley K, Rubin P et al (1980) A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45:2744–2753

    CAS  Google Scholar 

  59. Bradley J, Graham MV, Winter K et al (2005) Toxicity and outcome results of RTOG 9311: a phase I-II dose escalation study using three-dimensional conformal radiation therapy in patients with inoperable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 61:318–328

    Article  PubMed  Google Scholar 

  60. Kong F, Gaspar LE, Komaki R et al (2007) Patterns of practice in radiation dose prescription and treatment planning for patients with lung cancer among members of American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 69[3 Suppl 1]:S483

    Article  Google Scholar 

  61. Huber RM, Flentje M, Schmidt M et al (2006) Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 24:4397–4404

    Article  PubMed  CAS  Google Scholar 

  62. Saunders M, Dische S, Barret A et al (1997) Continuous hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomized multicentre trial. CHART Steering Committee. Lancet 350:161–169

    Article  PubMed  CAS  Google Scholar 

  63. Saunders M, Dische S, Barret A et al (1999) Continuous hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cáncer: mature data from the randomized multicentre trial. CHART Steering Committee. Radiother Oncol 52: 137–143

    Article  CAS  Google Scholar 

  64. Belani CP, Wang W, Johnson DH et al (2005) Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B nonsmall cell lung cancer. J Clin Oncol 23:3760–3769

    Article  PubMed  CAS  Google Scholar 

  65. Schild SE, Stella PJ, Geyer SM et al (2002) Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 54:370–378

    Article  PubMed  Google Scholar 

  66. Kong FM, Ten Haken RK, Schipper MJ et al (2005) High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63:324–333

    Article  PubMed  Google Scholar 

  67. Wang L, Correa CR, Zhao L et al (2009) The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 73:1383–1390

    Article  PubMed  CAS  Google Scholar 

  68. Bradley J, Graham MV, Winter K et al (2005) Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using threedimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61:318–328

    Article  PubMed  Google Scholar 

  69. Rosenman JG, Halle JS, Socinski MA et al (2002) High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54:348–356

    Article  PubMed  Google Scholar 

  70. Schild SE, McGinnis WL, Graham D et al (2006) Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 65:1106–1111

    Article  PubMed  CAS  Google Scholar 

  71. Bradley JD, Moughan J, Graham MV et al (2010) A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 77:367–372

    Article  PubMed  CAS  Google Scholar 

  72. ICRU Report 62 (1999) Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50). International Commission on Radiation Units and Measurements

  73. MacManus M, Nestle U, Rosenzweig KE et al (2009) Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol 91:85–94

    Article  PubMed  Google Scholar 

  74. De Ruysscher D, Kirsch CM (2010) PET scans in radiotherapy planning of lung cancer. Radiother Oncol 96:335–338

    Article  PubMed  Google Scholar 

  75. Yuan S, Sun X, Li M et al (2007) A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III non-small cell lung cancer. Am J Clin Oncol 30:239–244

    Article  PubMed  CAS  Google Scholar 

  76. Rosenzweig KE, Sura S, Jackson A et al (2007) Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 25:5557–5561

    Article  PubMed  Google Scholar 

  77. Sulman EP, Komaki R, Klopp AH et al (2009) Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 30:4–5

    Google Scholar 

  78. Sanuki-Fujimoto N, Sumi M, Ito Y et al (2009) Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses. Radiother Oncol 91:433–437

    Article  PubMed  Google Scholar 

  79. Fernandes AT, Shen J, Finlay J et al (2010) Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes. Radiother Oncol 95:178–184

    Article  PubMed  Google Scholar 

  80. Belderbos JS, Kepka L, Spring Kong FM et al (2008) Report from the International Atomic Energy Agency (IAEA) consultants’ meeting on elective nodal irradiation in lung cancer: nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 72:335–342

    Article  PubMed  Google Scholar 

  81. Liao ZX, Komaki RR, Thames HD Jr et al (2010) Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76:775–781

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Radioterápica, Hospital Ramón y Cajal, Ctra. Colmenar, km. 9,100, ES-28034, Madrid, Spain

    Carmen Vallejo Ocaña

  2. Servicio de Oncología Médica, Hospital Ramón y Cajal, Madrid, Spain

    Pilar Garrido López

  3. Servicio de Cirugía Torácica, Hospital Ramón y Cajal, Madrid, Spain

    Ignacio Muguruza Trueba

Authors
  1. Carmen Vallejo Ocaña
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pilar Garrido López
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ignacio Muguruza Trueba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmen Vallejo Ocaña.

Additional information

Supported by an unrestricted educational grant from MSD Oncology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ocaña, C.V., López, P.G. & Trueba, I.M. Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions. Clin Transl Oncol 13, 629–635 (2011). https://doi.org/10.1007/s12094-011-0708-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-011-0708-8

Keywords

Search

Navigation